Marketa Jelinkova

Title: Marketa Jelinkova: Innovator in Targeted Cancer Therapy

Introduction

Marketa Jelinkova is a prominent inventor based in Prague, Czech Republic. She has made significant contributions to the field of targeted cancer therapy through her innovative research and development. Her work focuses on creating advanced polymeric conjugates that enhance the efficacy of cancer treatments.

Latest Patents

Marketa holds a patent for "PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy." This invention involves conjugates consisting of a polymeric carrier made up of 30 to 3,000 monomer units linked to form a polymeric chain. The composition includes 60 to 99% of N-(2-hydroxypropyl)methacrylamide units, 1 to 25% of methacryloylated hydrazones of α-amino acids, ε-amino acids, aromatic amino acids, or oligopeptides terminated with an anthracycline cancerostatic molecule, and 0.5 to 15% of methacryloylated α-amino acids, ε-amino acids, aromatic amino acids, or oligopeptides or their sodium salts. This innovative approach aims to improve targeted therapy for cancer patients.

Career Highlights

Marketa is currently associated with Zentiva a.s., where she continues to advance her research in pharmaceutical sciences. Her dedication to innovation in cancer treatment has positioned her as a key figure in her field.

Collaborations

Throughout her career, Marketa has collaborated with esteemed colleagues such as Karel Ulbrich and Tomas Etrych. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking therapies.

Conclusion

Marketa Jelinkova's contributions to targeted cancer therapy through her innovative patent demonstrate her commitment to improving patient outcomes. Her work continues to inspire advancements in the field of oncology.